Dynulta Tablet

Dynulta Tablet contains the active component sucroferric oxyhydroxide. It is classified as a phosphate binder. This medication treats hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Hyperphosphatemia is characterized by abnormally high levels of phosphate in the blood, a common complication of CKD. This medicine contains iron, which can benefit individuals with CKD who often experience iron deficiency anemia. Providing iron and phosphate binding helps address iron deficiency and support red blood cell production.